Clinical trial · Interventional
Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases
NCT02301858CI-TRIAL-00063378unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Metastases | Lung Neoplasm | PROBABILISTIC | 0.70 |
| Primary Tumor | Primary Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genome analysis of tissue samples. | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Study arm
- description
- Genome analysis of tissue samples.
- interventionNames
- Genetic: Genome analysis of tissue samples.
Primary outcomes (1)
- measure
- Comparing histopathological and molecular characteristics of tumour tissue from metastases with the primary tumour in the lung
- timeFrame
- 5 years
- description
- We will do profiling of the mRNA (messenger ribonucleic acid) expression of microRNA and perform single nucleotide polymorphism analysis of cancer tissue and compare the expression using statistical methods such as SAM (Significance analysis and microarrays), PAM (Prediction analysis of microarrays). In addition, we wish to perform specific genetic analysis of cancer-related genes. These will be made with available methods like sequencing or TaqMan assays for specific mutations. Blood samples will be analysed by microarray methods for RNA and microRNA in addition to serum analysis of proteins.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastasizing lung cancer where further treatment is still applicable. Exclusion Criteria: * Terminal patients or patients in a reduced general condition with EGOC 3-4, i.e. patients who are confined to bed more than 50% of the day, with no clinical indication to perform sampling of the tumor and metastases. * Patients where further cancer treatment is no longer applicable. * Patients with cognitive impairment. * Patients with inaccessible metastases where sampling may cause distress to the patient and are at increased risk of complications.
References
Publications (0)
Data not yet available
No reference posted for this study.